BusinessPostCorner.com
No Result
View All Result
Thursday, June 5, 2025
  • Home
  • Business
  • Finance
  • Accounting
  • Tax
  • Management
  • Marketing
  • Crypto News
  • Human Resources
BusinessPostCorner.com
  • Home
  • Business
  • Finance
  • Accounting
  • Tax
  • Management
  • Marketing
  • Crypto News
  • Human Resources
No Result
View All Result
BusinessPostCorner.com
No Result
View All Result

US pharma boss calls tariffs a ‘pivotal moment’

April 3, 2025
in Business
Reading Time: 3 mins read
A A
0
US pharma boss calls tariffs a ‘pivotal moment’
ShareShareShareShareShare

The boss of US pharmaceutical giant Eli Lilly says there is no looking back from Donald Trump’s decision to impose sweeping tariffs on imports from the rest of the world.

In an exclusive interview with the BBC, David Ricks described it as a watershed moment in US economic history, “I think it’s a pivot in US policy and it feels like it’ll be hard to come back from here.”

While Mr Ricks said he thought it may encourage some companies to relocate some manufacturing, he was doubtful it would also create hundreds of billions in additional revenue for the US promised by President Trump.

He also added that the UK’s status as a pharmaceutical and life sciences power was in decline.

Eli Lilly is a pharmaceutical giant worth $750 billion with 50,000 employees across the US, Europe and Asia.

Because of their complex supply chains and the often life saving products they make, pharmaceutical companies along with microchip makers were temporarily exempted from the tariffs imposed on all products imported into the US.

But Mr Ricks seemed in little doubt that tariffs would eventually hit and that would have damaging consequences for investment in new medicines.

He explained that drug prices were essentially capped in Europe and the US which meant the impact of tariffs would be felt elsewhere.

“We cant breach those agreements so we have to eat the cost of the tariffs and make trade offs within our own companies. Typically that will be in reduction of staff or research and development and I predict R&D will come first. That’s a disappointing outcome.”

Mr Ricks said he did not support the imposition of tariffs but understood its intention and respected Mr Trump’s political mandate.

“We don’t support tariffs, to be clear. In pharma, about 70% of global R&D takes place in the United States. So we’re creating the next generation of breakthroughs and cures. But the production is heavily weighted outside the US. And that’s not unique to our industry. It happened with electronics and software and other things”.

“So I think what this administration is saying is we want both. We want the means of production and we want the research and development intellectual property generation.”

Eli Lilly are in the process of building a new additional £800 million facility in Limerick in Ireland where they employ over 3,000 people. Mr Ricks said that development would proceed.

“There’s plenty of demand outside the US so we’d have to look at the flow of goods because we wouldn’t want to have to pay tariffs if we didn’t need to but I think for the moment that’s fine.”

But Mr Ricks said that its investment in the UK had been in decline and warned that slow regulation and poor uptake of new medicines threatened the UK’s reputation as an important life sciences hub and that patients were missing out on new advances in medicine.

Mr Ricks said he delivered some “candid” comments to senior ministers including the Prime Minister, Health Secretary and Business Secretary.

“The UK’s advantage is slipping. If you look at the numbers there is disinvestment in research and development. It’s been on a steady decline.”

So is the UK complacent when it thinks of itself as a life sciences super power?

“That’s one way to put it.”

Mr Ricks said countries like Germany spend nearly double of their health budget on medicines.

“The UK is not a large market. But what it could be is an exceptional market. You need three things to make our industry work. A strong intellectual property system, and the UK is quite good. You need a regulator that’s timely efficient and predictable – pretty good there as well but most importantly you need a commercial market that rewards innovation – and here there’s been significant backsliding”.

Credit: Source link

ShareTweetSendPinShare
Previous Post

Mitsubishi UFJ ‘On Verge of Launching Japan’s First Stablecoin’

Next Post

Tax Fraud Blotter: Big plans

Next Post
Tax Fraud Blotter: Big plans

Tax Fraud Blotter: Big plans

To succeed at succession, ask yourself these hard questions

To succeed at succession, ask yourself these hard questions

May 29, 2025
Accountants on IRS and PwC layoffs, accounting students and more

Accountants on IRS and PwC layoffs, accounting students and more

June 5, 2025
Gen Z and boomers are driving a leadership vacuum that’s threatening productivity and morale at work

Gen Z and boomers are driving a leadership vacuum that’s threatening productivity and morale at work

May 31, 2025
BlackRock removed from Texas blacklist after climate policy rollback

BlackRock removed from Texas blacklist after climate policy rollback

June 3, 2025
Chinese couple arrested for smuggling a fungus, considered a biological pathogen, in a wad of tissues

Chinese couple arrested for smuggling a fungus, considered a biological pathogen, in a wad of tissues

June 4, 2025
Bitcoin Price Prediction: BTC Eyes Breakout on Trump ETF and Global Demand

Bitcoin Price Prediction: BTC Eyes Breakout on Trump ETF and Global Demand

June 5, 2025
BusinessPostCorner.com

BusinessPostCorner.com is an online news portal that aims to share the latest news about following topics: Accounting, Tax, Business, Finance, Crypto, Management, Human resources and Marketing. Feel free to get in touch with us!

Recent News

DOJ seizes crypto and 145 domains from BidenCash marketplace

DOJ seizes crypto and 145 domains from BidenCash marketplace

June 5, 2025
Family shocked at rental costs in Guernsey

Family shocked at rental costs in Guernsey

June 5, 2025

Our Newsletter!

Loading
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • DMCA

© 2023 businesspostcorner.com - All Rights Reserved!

No Result
View All Result
  • Home
  • Business
  • Finance
  • Accounting
  • Tax
  • Management
  • Marketing
  • Crypto News
  • Human Resources

© 2023 businesspostcorner.com - All Rights Reserved!